SCHEDULE 13G/A: Millennium Entities Reduce Passive Stake in Pyxis Oncology, Inc. to 4.0%

Millennium Management LLC and its affiliated entities have filed an amended Schedule 13G, disclosing a reduction in their passive beneficial ownership of Pyxis Oncology, Inc.'s common stock to 4.0% as of March 31, 2025.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amendment to their Schedule 13G regarding Pyxis Oncology, Inc.
• As of March 31, 2025, the reporting persons collectively beneficially own 2,488,079 shares of Pyxis Oncology, Inc. common stock.
• This aggregate amount represents 4.0% of the outstanding common stock of Pyxis Oncology, Inc.
• The filing indicates that the shares are held with shared voting and shared dispositive power among the reporting entities.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Pyxis Oncology, Inc.

Sentiment

Score: 3

Explanation: The reduction of a significant institutional investor's stake below the 5% reporting threshold is generally perceived as a negative signal, indicating a potential decrease in confidence or a portfolio rebalancing.

Positives

• The continued, albeit reduced, passive investment by a prominent institutional investor like Millennium Management LLC may still signal some level of confidence in Pyxis Oncology, Inc.

Negatives

• The beneficial ownership by Millennium Management LLC and its affiliates has decreased to 4.0%, falling below the 5% threshold that typically triggers an initial Schedule 13G filing, indicating a reduction in their stake.

Risks

• The reduction in beneficial ownership by a significant institutional investor could be perceived negatively by the market, potentially impacting investor sentiment and the company's stock price.
• While the filing states the investment is passive, a substantial reduction in stake by a large fund could suggest a re-evaluation of the investment's prospects by that fund.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance from Pyxis Oncology, Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by reporting persons)

Industry Context

This filing is a routine disclosure of institutional ownership changes within the public markets. It reflects a portfolio adjustment by a major hedge fund in a publicly traded biotechnology company, Pyxis Oncology, Inc., rather than a specific industry trend.

Stakeholder Impact

• Shareholders of Pyxis Oncology, Inc. may react negatively to the news of a significant institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
• The reduction in institutional ownership could affect the company's liquidity and trading volume.

Next Steps

• The reporting persons are no longer required to file Schedule 13G amendments unless their beneficial ownership of Pyxis Oncology, Inc. common stock again exceeds 5%.

Key Dates

Recommendation

Keywords

Pyxis Oncology, Millennium Management, Schedule 13G/A, beneficial ownership, institutional investment, common stock, passive investment